Description: The peptide sequence CEAITKTNL is a 9-amino-acid fragment that has been identified as a potential T-cell epitope through computational prediction methods. While it has not been extensively characterized in experimental studies, its sequence suggests it may be derived from the carcinoembryonic antigen (CEA), a glycoprotein overexpressed in various cancers, including colorectal, pancreatic, and gastric cancers. Role in T-Cell Epitope Prediction: Computational tools, such as those provided by the Immune Epitope Database (IEDB), are commonly used to predict peptide sequences that can bind to major histocompatibility complex (MHC) molecules and be recognized by T cells . The CEAITKTNL sequence has been identified in such analyses as a candidate epitope that could potentially elicit a T-cell response. However, without experimental validation, its immunogenicity and relevance in vivo remain speculative. Potential Applications in Immunotherapy If experimentally confirmed, peptides like CEAITKTNL could have several applications: Cancer Vaccines: As a potential tumor-associated antigen, this peptide could be used to develop vaccines aimed at inducing a targeted immune response against cancer cells expressing CEA. Adoptive T-Cell Therapy: T cells engineered to recognize this epitope could be employed to target and destroy tumor cells in patients. Diagnostic Tools: Detection of T-cell responses to this peptide could serve as a biomarker for immune monitoring in cancer patients. CEAITKTNL is a computationally predicted peptide that may serve as a T-cell epitope derived from carcinoembryonic antigen. While it holds potential for applications in cancer immunotherapy and diagnostics, further experimental studies are necessary to validate its immunogenicity and therapeutic utility. | The peptide sequence CEAITKTNL is a 9-amino-acid fragment that has been identified as a potential T-cell epitope through computational prediction methods. While it has not been extensively characterized in experimental studies, its sequence suggests it may be derived from the carcinoembryonic antigen (CEA), a glycoprotein overexpressed in various cancers, including colorectal, pancreatic, and gastric cancers. Role in T-Cell Epitope Prediction: Computational tools, such as those provided by the Immune Epitope Database (IEDB), are commonly used to predict peptide sequences that can bind to major histocompatibility complex (MHC) molecules and be recognized by T cells . The CEAITKTNL sequence has been identified in such analyses as a candidate epitope that could potentially elicit a T-cell response. However, without experimental validation, its immunogenicity and relevance in vivo remain speculative. Potential Applications in Immunotherapy If experimentally confirmed, peptides like CEAITKTNL could have several applications: Cancer Vaccines: As a potential tumor-associated antigen, this peptide could be used to develop vaccines aimed at inducing a targeted immune response against cancer cells expressing CEA. Adoptive T-Cell Therapy: T cells engineered to recognize this epitope could be employed to target and destroy tumor cells in patients. Diagnostic Tools: Detection of T-cell responses to this peptide could serve as a biomarker for immune monitoring in cancer patients. CEAITKTNL is a computationally predicted peptide that may serve as a T-cell epitope derived from carcinoembryonic antigen. While it holds potential for applications in cancer immunotherapy and diagnostics, further experimental studies are necessary to validate its immunogenicity and therapeutic utility. |
Scientific Background | CEAITKTNL is a 9-residue synthetic peptide with the sequence Cys-Glu-Ala-Ile-Thr-Lys-Thr-Asn-Leu. The sequence contains 1 cysteine residue, providing potential thiol/disulfide chemistry when the thiol is available. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence. |
Experimental Notes | Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions. |
